As the U.S. market approaches record highs, with the S&P 500 nearing its peak and the Dow Jones Industrial Average inching closer to a new high, investor sentiment is being shaped by ongoing trade uncertainties and robust earnings reports from sectors like airlines. In this dynamic environment, identifying high-growth tech stocks requires a keen understanding of their potential to capitalize on technological advancements and market trends that are currently influencing broader indices.
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
---|---|---|---|
Super Micro Computer |
24.75% |
38.20% |
★★★★★★ |
Circle Internet Group |
30.78% |
60.64% |
★★★★★★ |
Ardelyx |
21.16% |
61.58% |
★★★★★★ |
Mereo BioPharma Group |
50.84% |
58.22% |
★★★★★★ |
TG Therapeutics |
26.46% |
38.75% |
★★★★★★ |
AVITA Medical |
27.42% |
61.04% |
★★★★★★ |
Alnylam Pharmaceuticals |
23.86% |
59.49% |
★★★★★★ |
Alkami Technology |
20.53% |
76.67% |
★★★★★★ |
Ascendis Pharma |
35.02% |
60.01% |
★★★★★★ |
Lumentum Holdings |
23.14% |
103.97% |
★★★★★★ |
Click here to see the full list of 227 stocks from our US High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Exact Sciences Corporation specializes in cancer screening and diagnostic test products, operating both in the United States and internationally, with a market cap of $10.10 billion.
Operations: The company generates revenue primarily from its biotechnology segment, which contributed $2.83 billion. Its focus on cancer screening and diagnostic tests positions it within the healthcare sector, targeting both domestic and international markets.
Exact Sciences is poised for significant advancements in the oncology sector, particularly with its recent Medicare coverage approval for the Oncodetect MRD test. This approval enhances its role in colorectal cancer management, potentially impacting over three million Americans eligible for MRD testing. The company's R&D focus is evident from its continued innovation, such as integrating Broad Institute's MAESTRO technology into their next-generation tests, promising ultra-low detection limits that could revolutionize cancer monitoring. With a revenue growth forecast of 10.2% annually and an anticipated profitability within three years, Exact Sciences demonstrates a robust trajectory in harnessing advanced diagnostics to improve cancer treatment outcomes.